Pricing Log in Create free account

Caribou Biosciences, Inc. (CRBU) vs Gain Therapeutics, Inc. (GANX)

Caribou Biosciences, Inc. and Gain Therapeutics, Inc. are both Biotechnology companies. Caribou Biosciences, Inc. and Gain Therapeutics, Inc. are of similar size ($44.2M and $41.9M). Gain Therapeutics, Inc. grew revenue faster over the last twelve months: 18.4% against 1.60%. Gain Therapeutics, Inc. has the higher net margin (0.00% vs −1,085.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Caribou Biosciences, Inc. leads on 9 and Gain Therapeutics, Inc. on 8.

Valuation

Metric CRBU GANX Biotechnology median
P/E n/m n/m 10.60
P/S 5.01 219.56 9.40
P/B 0.62 3.80 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.45 n/m 0.66
EV/Sales (5.03) 154.32 9.02
Earnings yield (234.09%) (50.00%) (32.88%)
Free cash flow yield (275.02%) (44.25%) (23.13%)

Profitability

Metric CRBU GANX Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin (1,140.55%) 0.00% 0.00%
Net margin (1,085.00%) 0.00% 0.00%
Free cash flow margin (985.95%) 0.00% 0.00%
Return on equity (93.80%) (268.30%) (51.96%)
Return on assets (64.44%) (159.22%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CRBU GANX Biotechnology median
Revenue growth (TTM) 1.60% 18.36% 6.76%
EPS growth (last fiscal year) 3.64% 31.46% 29.88%
Revenue growth, 5-year CAGR (2.03%) 21.79% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRBU GANX Biotechnology median
Debt to equity 0.00 0.03 0.00
Current ratio 4.97 4.36 4.97
Net debt to EBITDA 0.96 1.10 1.01

Dividend

Metric CRBU GANX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CRBU GANX Biotechnology median
Market cap 44.20m 41.91m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack